A practical reference on 双受体激动: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-13 and is reviewed periodically as new material appears.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Providing oral health education. Re-cementing crowns with temporary cement. Providing anti-snoring devices. Removing sutures after the wound has been checked by a dentist. Prescribing radiographs. Replacing implant abutments for dental appliances. Providing tooth whitening treatments.
Esketamine inhibits the dopamine transporter about 8-fold more potently than does arketamine, and so is about 8 times more potent as a dopamine reuptake inhibitor. Arketamine and esketamine possess similar potency for interaction with the muscarinic acetylcholine receptors.
Topical nonsteroidal anti-inflammatory drugs provide pain relief in common conditions such as muscle sprains and overuse injuries. Since the side effects are also lesser, topical preparations could be preferred over oral medications in these conditions.
. R is the gas constant and T is the absolute temperature. Note that pKa = −log(Ka) and 2.303 ≈ ln(10). At 25 °C, ΔG⊖ in kJ·mol−1 ≈ 5.708 pKa (1 kJ·mol−1 = 1000 joules per mole). Free energy is made up of an enthalpy term and an entropy term.
Sources: en.wikipedia.org
== Behavior == Male and female king bettas flare or puff out their gills in order to appear more impressive, either to intimidate rivals or attract mates, as well as when they are startled. Females often flare their gills at other females (rare in B. splendens.) All bettas require a place to hide occasionally, even in solitary tanks. They may set up a territory centered on a plant or rock, which they will guard aggressively. This breed is not appropriate for a typical community tank due to its aggressiveness, particularly towards species of fish with long, flowing fins.
An unexpected series of experimental results for the rate of decay of heavy highly charged radioactive ions circulating in a storage ring provoked theoretical activity in an effort to find a convincing explanation. The rates of weak decay of two radioactive species with half-lives of about 40 s and 200 s were reported to have a significant oscillatory modulation, with a period of about 7 s. The reported phenomenon is known as the GSI anomaly, as the storage ring is a facility at the GSI Helmholtz Centre for Heavy Ion Research in Darmstadt, Germany. As the decay process produces an electron neutrino, some of the proposed explanations for the observed rate oscillation invoked neutrino properties. Initial ideas related to flavour oscillation met with skepticism. A 2016 proposal involved mass differences between neutrino mass eigenstates. In a follow-up study published in 2019, measurements of about 9,000 electron-capture decays of hydrogen-like promethium-142 ions showed no periodic modulation. The results were consistent with exponential decay.
== Global demand == Global EO demand has expanded from 16.6 Mt (18.3 million short tons) in 2004 to 20 Mt (22 million short tons) in 2009, while demand for refined EO expanded from 4.64 Mt (5.11 million short tons) in 2004 to 5.6 Mt (6.2 million short tons) in 2008. In 2009, demand is estimated to have declined to about 5.2 Mt (5.7 million short tons). Total EO demand registered a growth rate of 5.6% per annum during the period 2005 to 2009 and is projected to grow at 5.7% per annum during 2009 to 2013.
Alexei Sayle (born 7 August 1952), English actor, author, stand-up comedian, television presenter and former recording artist; voted the 18th greatest stand-up comic of all time on Channel 4's 100 Greatest Stand-Ups in 2007; In an updated 2010 poll he came 72nd. has written two short story collections, five novels, including a graphic novel and a radio series spin-off book, as well as columns for various publications; has written for Time Out and the Sunday Mirror; was one of eight contributory authors to the BBC Three competition End of Story. Simon Schama (born 13 February 1945), author of Lithuanian Jewish ancestry, specialising in art history, Dutch history, Jewish history, and French history. He is a University Professor of History and Art History at Columbia University, New York. Isaac Schapera FBA FRAI (23 June 1905 Garies, Cape Colony – 26 June 2003 London, England); of South African Jewish-Russian Jewish ancestry; author of numerous highly regarded anthropology books and over 200 monographs and scholarly academic papers on Africa;social anthropologist at London School of Economics specialising in South Africa; notable for his ethnographic and typological studies of the indigenous peoples of Botswana and South Africa; one of the founders of group that would develop British social anthropology, and students included important figures of anthropology, such as Ernest Gellner, Eileen Krige, Hilda Kuper, Max Gluckman, John Comaroff, Johan Frederik Holleman and Jean Comaroff.
Several studies have also found these tests to be less sensitive than skin testing for the detection of clinically relevant allergies. False positive results may be obtained due to cross-reactivity of homologous proteins or by cross-reactive carbohydrate determinants (CCDs). In the NIH food guidelines issued in December 2010 it was stated that "The predictive values associated with clinical evidence of allergy for ImmunoCAP cannot be applied to other test methods." With over 4000 scientific articles using ImmunoCAP and showing its clinical value, ImmunoCAP is perceived as "Gold standard" for in vitro IgE testing
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.